Sarah Pringle

How the CARES Act may affect PE-backed healthcare companies and New Mountain Capital's sale of Equian wins Deal of the Year.

In three-and-a-half years, New Mountain Capital catapulted growth at Equian and expanded headcount by 72%, all while earning a return of $2bn and the top award for deals made in 2019.

The commercial brokerage firm has struck 18 add-ons since 2018 and has another 10 on its radar in the near term with a new capital infusion from HGGC, the firm's Steve Young told PE Hub.

Moelis and Barclays are said to have scored the sell-side advisor mandate shortly before coronavirus-related fears drove U.S. financial markets into extreme volatility.

While Varma is supportive of a shutdown, he said the medical damage to patients with other diseases is going to become insurmountable.

PE firms move slowly into offense mode amid the coronavirus crisis and Thoma Bravo shelves its sale of Imprivata.

Across the private equity industry, the impacts of the pandemic-spurred economic downturn are being felt in dealmaking, which has slowed or paused fundraising processes while LPs work to understand the status of their portfolios.

While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.

Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.

Areas of the healthcare industry will likely be triggered into action, spurring innovation, as bottlenecks in the system become increasingly clear amid covid-19, Adams told PE Hub.